Abstract: Provided is a humanized anti-CD22 recombinant immunotoxin, which has reduced immunogenicity and maintains the CD22 binding affinity and corresponding biological activity before humanization transformation, and is used for preparing a drug for treating CD22-related B cell malignant tumors.

Abstract: Provided in the present invention is an isolated anti-CD22 antibody or an antigen-binding fragment thereof, and further provided is the use thereof. The antibody or the antigen binding fragment thereof shows strong identification capability for and a high affinity to CD22 recombinant protein and a CD22 positive cell line, a strong internalization capability to enter the CD22 positive cell line, and an effective growth inhibition and cell apoptosis effect on the CD22 positive cell line after fusion with bacterial exotoxin.

Abstract: Amlodipine mesylate monohydrate, a preparation method therefor and a use thereof. The described amlodipine mesylate monohydrate has high purity, has good fluidity and compressibility, and is suitable for direct tableting processing by a high-speed tablet press.